ADC Therapeutics SA (ADCT)

Business: ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors.

IPO Date: 16-Mar-1979

Pres & CEO: Dr. Ameet Mallik

Vice Chairman, Exec. VP & Gen. Counsel: Mr. Michael Forer L.L.B.

Listing: NYSE: ADCT

Country: Switzerland

Headquarters: Epalinges,

Website: https://www.adctherapeutics.com

Market cap: $594.51 Mln

Revenue (TTM): $80.42 Mln

Earnings (TTM): $-195.16 Mln

Cash: $430.87 Mln

Total Debt: $0.00 Mln

Insider's Holding: 52.35%

Liquidity: Low

52 Week range: $5.52 - 32.00

Shares outstanding: 76,810,496

5 Years Aggregate:

• CFO: $-720.00 Mln
• EBITDA: $-794.51 Mln
• Net Profit: $-805.76 Mln